Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Amplia Therapeutics ( (AU:ATX) ).
Amplia Therapeutics announced a positive development in its ACCENT trial for metastatic pancreatic cancer, where its FAK inhibitor narmafotinib, combined with gemcitabine and nab-paclitaxel, achieved a 35% objective response rate. This result surpasses the 23% response rate of the benchmark MPACT trial, indicating a significant advancement in treatment efficacy. The data will be presented at the Life Sciences Virtual Investor Forum, highlighting Amplia’s potential impact on cancer treatment and its strategic positioning in the pharmaceutical industry.
The most recent analyst rating on (AU:ATX) stock is a Hold with a A$0.12 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
More about Amplia Therapeutics
Amplia Therapeutics Limited is an Australian pharmaceutical company focused on developing Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company targets fibrotic cancers such as pancreatic and ovarian cancer, and FAK is also relevant in chronic diseases like idiopathic pulmonary fibrosis (IPF).
Average Trading Volume: 1,119,429
Technical Sentiment Signal: Sell
Current Market Cap: A$64.13M
For an in-depth examination of ATX stock, go to TipRanks’ Overview page.